Abstract 606: Targeting the immune checkpoint PTPN2 with ABBV-CLS-484 inflames the tumor microenvironment and unleashes potent CD8+ T cell immunity

Arvin Iracheta‐Vellve(Broad Institute), Robert T. Manguso(Broad Institute), Hakimeh Ebrahimi-Nik(Broad Institute), Andrew S. Boghossian(University of California, San Francisco), James C. Patti(Broad Institute), Jennifer M. Frost(Mount Sinai Hospital), Philip R. Kym(AbbVie (United States)), Clay Beauregard, Cun Lan Chuong(Broad Institute), Mitchell D. Yeary(Broad Institute), Jennifer A. Roth(Broad Institute), Ian C. Kohnle(Broad Institute), Elliot P. Farney(AbbVie (United States)), Kathleen A. McGuire(AbbVie (United States)), Keith M. Hamel(AbbVie (United States)), Matthew G. Rees(Broad Institute), Kathleen B. Yates(Broad Institute), Gabriel K. Griffin(Harvard University), Kira E. Olander(Broad Institute), Zhaoming Xiong(AbbVie (United States)), Sarah Kim(University of Miami), Christina K. Baumgartner(AbbVie (United States)), Todd R. Golub(Broad Institute), Thomas R. A. Davis(Broad Institute), Melissa M. Ronan(Broad Institute)
Cancer Research
June 15, 2022
Cited by 8


Related Papers